These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2502156)

  • 1. Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS.
    Lange J; Vahlne A; Dekker J; de Wolf F; Goudsmit J
    AIDS; 1989 Jun; 3(6):402-3. PubMed ID: 2502156
    [No Abstract]   [Full Text] [Related]  

  • 2. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 3. Rapid development of AIDS in an HIV-1-antibody-negative homosexual man.
    Martin-Rico P; Pedersen C; Skinhøj P; Nielsen C; Lindhardt BO
    AIDS; 1995 Jan; 9(1):95-6. PubMed ID: 7893450
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnosis and the methods of evaluating the degree of impairment of the immune system in HIV infection].
    Radkowski M; Laskus T
    Pol Arch Med Wewn; 1992 Jun; 87(6):372-8. PubMed ID: 1357632
    [No Abstract]   [Full Text] [Related]  

  • 5. New tests produced by Organon Teknika for the diagnosis of antibodies to HIV-1 and HIV-2.
    Chantrain C
    Przegl Epidemiol; 1992; 46(1-2):3-10. PubMed ID: 1475387
    [No Abstract]   [Full Text] [Related]  

  • 6. [Affinity of anti-HIV antibodies in patients with asymptomatic and symptomatic HIV infection].
    Radkowski M; Laskus T; Goch A; Babiuch L; Slusarczyk J
    Przegl Epidemiol; 1991; 45(4):369-72. PubMed ID: 1841418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AIDS and Trojan horses.
    Elder D; Harris R
    Riv Biol; 1992; 85(2):247-8. PubMed ID: 1361074
    [No Abstract]   [Full Text] [Related]  

  • 8. Protective immunity against HIV infection: lessons from HIV-2 infection.
    Rowland-Jones S
    Future Microbiol; 2006 Dec; 1(4):427-33. PubMed ID: 17661633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Status of HIV vaccine development.
    Minor JR
    Am J Hosp Pharm; 1994 Jul; 51(14):1816-8. PubMed ID: 7942913
    [No Abstract]   [Full Text] [Related]  

  • 10. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group.
    Montefiori DC; Lefkowitz LB; Keller RE; Holmberg V; Sandstrom E; Phair JP
    AIDS; 1991 May; 5(5):513-7. PubMed ID: 1863402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative results of a rapid antibody test for HIV in a 16-month-old infant with AIDS.
    Zhang Y; Wang J; Wilson GJ; Tang YW; Lu HZ
    Ann Clin Lab Sci; 2008; 38(3):293-5. PubMed ID: 18715861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The absence of loss of antibodies of high affinity to human immunodeficiency virus (HIV) is associated with disease progression in HIV-1-infected patients.
    Chargelegue D; Stanley CM; O'Toole CM; Colvin BT; Steward MW
    J Infect Dis; 1995 Sep; 172(3):897-8. PubMed ID: 7658093
    [No Abstract]   [Full Text] [Related]  

  • 13. Urgently needed: a filter for the HIV-1 vaccine pipeline.
    Moore JP; Burton DR
    Nat Med; 2004 Aug; 10(8):769-71. PubMed ID: 15286768
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment.
    Luo M; Yuan F; Liu Y; Jiang S; Song X; Jiang P; Yin X; Ding M; Deng H
    Vaccine; 2006 Jan; 24(4):435-42. PubMed ID: 16143433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-HIV antibodies: the source of specificity.
    Vaz NM
    Braz J Med Biol Res; 1992; 25(11):1059-61. PubMed ID: 1342585
    [No Abstract]   [Full Text] [Related]  

  • 16. Dual HIV-1 and HIV-2 infection in West Africa supported by synthetic peptide analysis.
    Cot MC; Poulain M; Delagneau JF; Peeters M; Brun-Vezinet F
    AIDS Res Hum Retroviruses; 1988 Aug; 4(4):239-41. PubMed ID: 3207511
    [No Abstract]   [Full Text] [Related]  

  • 17. Dual Immunity Concomitantly Suppresses HIV-1 Progression.
    Qureshi H; Bhattacharya J
    Trends Microbiol; 2017 May; 25(5):334-335. PubMed ID: 28284876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyclonal antibodies to mannan from yeast also recognize the carbohydrate structure of gp120 of the AIDS virus: an approach to raise neutralizing antibodies to HIV-1 infection in vitro.
    Müller WE; Schröder HC; Reuter P; Maidhof A; Uhlenbruck G; Winkler I
    AIDS; 1990 Feb; 4(2):159-62. PubMed ID: 2183815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retesting of sera for antibodies to HIV-1/HIV-2.
    Commun Dis Rep CDR Wkly; 1996 May; 6(18):153. PubMed ID: 8935418
    [No Abstract]   [Full Text] [Related]  

  • 20. A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera.
    Ghetie V; Wheeler T; Scott D; Uhr JW; Vitetta ES
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1945-8. PubMed ID: 1489581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.